Since 1980, scientists at Amgen have devoted themselves to providing novel therapies for patients with serious illness. Our growth from a biotech pioneer to an industry leader was driven by this commitment to find new ways to unlock the potential of biology for patients.
We believe that biotechnology can maximize this potential by providing more sophisticated ways to attack disease. Amgen was among the first companies to develop therapeutic proteins, which can replace or augment beneficial human proteins, and monoclonal antibodies, which can strike disease targets with enhanced precision. Our scientists have also engineered new types of medicines, such as peptibodies, and our pipeline features other entirely novel treatment modalities.
This commitment to therapeutic innovation is accompanied by a strong presence on the frontiers of human biology. Advances in human genetics are shedding new light on the molecular roots of disease. Amgen’s goal is to turn these insights into new and highly differentiated therapies. As a science-driven company, we pursue this goal through substantial internal investments, and we also leverage external innovation to complement our core capabilities.
The success of Amgen R&D can be seen in our product portfolio, which includes novel therapies for hard-to-treat diseases. These therapies have been used to treat more than 25 million patients worldwide with diseases that include cancer, kidney failure, blood and autoimmune disorders, and bone diseases. We are building on these successes with a drug pipeline that aims to help patients with conditions such as heart disease, schizophrenia, and migraine.
Understanding the fundamental biological mechanisms of human life is a defining feature of Amgen's discovery research efforts—and a major contributor to the development of Amgen's deep and broad pipeline of potential new medicines. Amgen's "biology first" approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. As advances in human genetics continue to shed new light on the molecular roots of disease, Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.